There is no question that there will be a buyout. The FDA "communication" recommending needle-free NOT be used for flu shots was the final straw. The company has little cash and few prospects for business; the CEO has left in order to conserve cash. The only thing left is the value of the technology and the associated IP. The company MUST be sold and, IMO, it will be sooner than later.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.